A Novel Insight into Postmenopausal Hypercholesterolemia: Carnitine as a Key Player
Metabolic Syndrome and Related Disorders · 2024
DOI: 10.1089/met.2024.0112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolic Syndrome and Related Disorders, 2024. Verfasst von Wu Lixing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medi…. Hauptthemen laut MEDLINE: Carnitine, Hypercholesterolemia, Postmenopause. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Endocrine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Huang Dan
Zitieren
APA
Lixing, W., Lin, C., Lijun, Y., Xiaojin, X., Zhuyang, S., Juan, Z., Linsheng, L., & Dan, H. (2024). A Novel Insight into Postmenopausal Hypercholesterolemia: Carnitine as a Key Player. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2024.0112
Vancouver
Lixing W, Lin C, Lijun Y, Xiaojin X, Zhuyang S, Juan Z, et al. A Novel Insight into Postmenopausal Hypercholesterolemia: Carnitine as a Key Player. Metabolic Syndrome and Related Disorders. 2024. doi:10.1089/met.2024.0112
BibTeX
@article{Lixing2024,
author = {Lixing, Wu and Lin, Cao and Lijun, Yang and Xiaojin, Xu and Zhuyang, Shen and Juan, Zhao and Linsheng, Liu and Dan, Huang},
title = {A Novel Insight into Postmenopausal Hypercholesterolemia: Carnitine as a Key Player},
journal = {Metabolic Syndrome and Related Disorders},
year = {2024},
doi = {10.1089/met.2024.0112}
}
EUVIMED